UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
____________________________________________________________
Date of Report (Date of earliest event reported): September 27, 2016
RASNA THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
| Nevada | 333- 191083 | 39-2080103 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) | ||
|
420 Lexington Avenue, New York, NY |
10170 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: 201-994-9936
Active With Me, Inc.
(Former name or former address, if changed since last report)
Copies to:
Jeffrey Fessler, Esq.
61 Broadway, 32nd Floor
New York, New York 10006
Telephone: (212) 930-9700
Facsimile: (212) 202-7735
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On September 27, 2016, Rasna Therapeutics, Inc. (the “Company”) issued a press release announcing that the Company effected a 3.25-for-1 forward split of its common stock, which went into effect for trading on a split-adjusted basis on Tuesday, September 20, 2016, as well as a name change and trading symbol change from Active With Me, Inc. and “ATVM” to Rasna Therapeutics, Inc. and “RASP,” effective as of September 27, 2016.
The information in this report (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits. |
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit No . | Description |
| 99.1 | Press Release issued September 27, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: September 27, 2016
| ACTIVE WITH ME, INC. | |||
| By: | /s/ James Tripp | ||
| Name: James Tripp | |||
| Title: Chief Executive Officer | |||
Exhibit 99.1
Rasna Therapeutics, Inc. Announces Forward Split of Common Stock, Name Change & Ticker Change to RASP
NEW YORK, NY – September 27, 2016 – Rasna Therapeutics, Inc. (OTCQB: RASP) (the “Company”) (formerly Active With Me, Inc.), a development stage biotechnology company focused on the development of cancer drugs, today announced it has implemented a 3.25-for-1 forward split of its common stock in effect for trading on a split-adjusted basis on Tuesday, September 20, 2016 as well as a name change and trading symbol change from Active With Me, Inc. and “ATVM” to Rasna Therapeutics, Inc. and “RASP”, effective as of September 27, 2016.
As a result of the stock split, every one share of issued and outstanding common stock of the Company will be converted into 3.25 shares of common stock. Proportional adjustments will be made to the Company's options and warrants. Any fractional shares resulting from the forward stock split will be rounded up to the next whole share.
###
About Rasna Therapeutics, Inc.
Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the development of drug candidates for leukemia and lymphoma. Abnormal epigenetic modification is recognized to play an important role in the pathogenesis of acute myeloid leukemia (AML), leading to silencing of genes involved in tumor suppression and cellular reproduction. Rasna’s focus on inhibition of lysine specific demethylase-1 (LSD1), an enzyme involved in epigenetic control, represents a promising and novel approach towards AML. Rasna has developed novel irreversible and reversible LSD1 regulators that have shown appropriate effects on the LSD1 gene in-vitro and in IND-enabling pre-clinical studies.
Rasna Therapeutics Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Rasna Therapeutics’ business and Rasna Therapeutics undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
| 1 |
Contact
James Tripp
Acting Chief Executive Officer
E-mail: jtripp@rasna.com
| Tel.: | +1 212-297-6288 |
Rasna Therapeutics Inc.
420 Lexington Avenue
Suite 2525
New York, NY 10170
USA
| 2 |